Search

Your search keyword '"Vaccines -- Marketing"' showing total 15 results
Start Over Descriptor "Vaccines -- Marketing" Publisher dow jones & company, inc.
15 results on '"Vaccines -- Marketing"'

1. Unit gets FDA approval to sell child-immunization vaccine

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Aventis-Pasteur Inc. -- Product information, Pharmaceutical industry -- Product information, Immunization of children -- Health aspects, Vaccines -- Marketing, Business, Business, general
Published
2002

3. SmithKline launching vaccine

Subjects
SmithKline Beecham PLC -- Marketing, Pharmaceutical industry -- Marketing, Vaccines -- Marketing, Business, Business, general
Published
1992

4. Merck & Co

Subjects
Merck & Company Inc. -- Joint ventures, Institut Merieux -- Joint ventures, Pharmaceutical industry -- Joint ventures, Vaccines -- Marketing, Business, Business, general
Published
1991

5. Vaccine case goes before high court

Author

Kendall, Brent

Subjects
United States. Supreme Court -- Cases, Wyeth -- Cases, Wyeth -- Marketing, Products liability -- Laws, regulations and rules, Vaccines -- Cases, Vaccines -- Marketing, Vaccines -- Complications and side effects, Vaccines -- Health aspects, Appellate courts -- Cases, Compensation (Law) -- Cases, Daughters -- Health aspects, Daughters -- Care and treatment, Daughters -- Injuries, Parents -- Cases, Pharmaceutical industry -- Marketing, Pharmaceutical industry -- Cases, Supreme Court justices -- Beliefs, opinions and attitudes, Company marketing practices, Government regulation, Company legal issue, News, opinion and commentary
Abstract

The United States Supreme Court is examining the case of Bruesewitz v. Wyeth, which will test whether some vaccine-makers are protected from product liability lawsuits in state courts. Some of the Supreme Court Justices are concerned that the gate could be opened to more such suits which could have a negative effect on the country's vaccine supplies. The case deals with a claim by the Pennsylvania parents of Hannah Bruesewitz, who allege that their daughter incurred a residual seizure disorder following the administration of a diphtheria, pertussis and tetanus vaccine manufactured by Wyeth when she was six months of age.

Published
2010

6. Abbott to buy Solvay drug unit for $7 billion; deal opens avenues to emerging markets while adding heart and hormone treatments as well as a flu vaccine

Author

Whalen, Jeanne, Cimilluca, Dana, and McCracken, Jeffrey

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Mergers, acquisitions and divestments, Solvay S.A. (Brussels, Belgium) -- Subsidiaries, divisions and units, Solvay S.A. (Brussels, Belgium) -- Mergers, acquisitions and divestments, Acquisitions and mergers -- Planning, Chemical industry -- Subsidiaries, divisions and units, Chemical industry -- Mergers, acquisitions and divestments, Herbicides -- Subsidiaries, divisions and units, Herbicides -- Mergers, acquisitions and divestments, Pesticides industry -- Subsidiaries, divisions and units, Pesticides industry -- Mergers, acquisitions and divestments, Drugs -- Marketing, Pharmaceutical industry -- Mergers, acquisitions and divestments, Subsidiary corporations -- Mergers, acquisitions and divestments, Vaccines -- Marketing, Company acquisition/merger, Company business planning, Company marketing practices, News, opinion and commentary
Published
2009

7. Head of Merck vaccine unit retires early as deal looms

Author

Loftus, Peter

Subjects
Merck & Company Inc. -- Officials and employees, Merck & Company Inc. -- Reorganization and restructuring, Merck & Company Inc. -- Subsidiaries, divisions and units, Pharmaceutical industry -- Officials and employees, Pharmaceutical industry -- Reorganization and restructuring, Pharmaceutical industry -- Subsidiaries, divisions and units, Presidents (Organizations) -- Appointments, resignations and dismissals, Presidents (Organizations) -- Evaluation, Subsidiary corporations -- Officials and employees, Vaccines -- Production management, Vaccines -- Marketing, Company restructuring/company reorganization, Company organization, Company marketing practices, News, opinion and commentary
Published
2009

8. Merck profit slips, but results top market forecast; merger costs, lower vaccine sales hurt drug maker; deal partner Schering-Plough increases earnings 45%

Author

Loftus, Peter

Subjects
Merck & Company Inc. -- Company sales and earnings, Schering-Plough Corp. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Profit -- Reports, Profit -- Forecasts and trends, Revenue -- Reports, Revenue -- Forecasts and trends, Sales -- Reports, Sales -- Forecasts and trends, Sales forecasting -- Reports, Vaccines -- Marketing, Sales analysis, Company earnings/profit, Market trend/market analysis, Company marketing practices, News, opinion and commentary
Published
2009

9. Wyeth vaccines also lured Pfizer; special court, 1986 act transformed sector into attractive product line

Author

Johnson, Avery

Subjects
Wyeth -- Mergers, acquisitions and divestments, Wyeth -- Product information, Pfizer Inc. -- Mergers, acquisitions and divestments, Actions and defenses -- Analysis, Children -- Health aspects, Courts -- United States, Courts -- Powers and duties, Courts -- Analysis, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Cases, Pharmaceutical industry -- Product information, Vaccines -- Cases, Vaccines -- Complications and side effects, Vaccines -- Marketing, Lawsuit/litigation, Company acquisition/merger, Company legal issue, Company marketing practices, Company product acquisition, Product marketing strategy, News, opinion and commentary
Published
2009

10. Sanofi Aventis expects global sales of vaccines to double

Author

Whalen, Jeanne

Subjects
Sanofi-Aventis S.A. -- Company sales and earnings, Sanofi-Aventis S.A. -- Capacity, Sanofi-Aventis S.A. -- Investments, Industrial capacity -- Planning, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Capacity, Pharmaceutical industry -- Investments, Sales -- Forecasts and trends, Sales -- International aspects, Vaccines -- Marketing, Company earnings/profit, Company investment, Company business planning, Market trend/market analysis, Company marketing practices, Sales analysis, News, opinion and commentary
Published
2008

11. Generics, vaccines help Novartis profit rise &%; U.S. setbacks hurt branded drugs; cost cuts contribute

Author

Whalen, Jeanne and Greil, Anita

Subjects
Novartis AG -- Company sales and earnings, Novartis AG -- Securities, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Securities, Profit -- Reports, Sales -- Statistics, Stocks -- Prices and rates, Vaccines -- Marketing, Sales analysis, Company earnings/profit, Company securities, Company pricing policy, Company marketing practices, News, opinion and commentary
Published
2008

12. Sanofi-Aventis profit rises on strong vaccine sales

Author

Bachelot-Fontaine, Laetitia

Subjects
Sanofi-Aventis S.A. -- Company sales and earnings, Sanofi-Aventis S.A. -- Securities, Drugs -- Marketing, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Securities, Profit -- Reports, Sales -- Statistics, Stocks -- Prices and rates, Vaccines -- Marketing, Sales analysis, Company earnings/profit, Company securities, Company marketing practices, Company pricing policy, News, opinion and commentary, Plavix (Medication) -- Marketing
Published
2007

13. Sanofi's bird-flu vaccine gets backing; outside panel advises FDA to approve use of likely stopgap

Author

Mathews, Anna Wilde and Whalen, Jeanne

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Sanofi-Aventis S.A. -- Product development, Sanofi-Aventis S.A. -- Laws, regulations and rules, Sanofi-Aventis S.A. -- Marketing, Pharmaceutical industry -- Product development, Pharmaceutical industry -- Laws, regulations and rules, Pharmaceutical industry -- Marketing, Avian influenza -- Prevention, Avian influenza -- Drug therapy, Vaccines -- Product development, Vaccines -- Laws, regulations and rules, Vaccines -- Marketing, Company marketing practices, Government regulation, News, opinion and commentary
Published
2007

14. Roche feels the highs and lows of feverish demand for Tamiflu

Author

Murray, Alan

Subjects
Roche Holding AG -- Company sales and earnings, Roche Holding AG -- Marketing, Roche Holding AG -- Licensing, certification and accreditation, Vaccines -- Marketing, Vaccines -- Licensing, certification and accreditation, Sales -- Reports, Profit -- Reports, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Marketing, Pharmaceutical industry -- Licensing, certification and accreditation, Licenses -- Management, Avian influenza -- Drug therapy, Sales analysis, Company marketing practices, Company earnings/profit, Company business management, News, opinion and commentary, Tamiflu (Medication) -- Licensing, certification and accreditation, Tamiflu (Medication) -- Marketing
Published
2005

15. Roche may let others produce Tamiflu amid global pressure

Author

Whalen, Jeanne and Zamiska, Nicholas

Subjects
Roche Holding AG -- Marketing, Roche Holding AG -- Licensing, certification and accreditation, Vaccines -- Marketing, Vaccines -- Licensing, certification and accreditation, Pharmaceutical industry -- Marketing, Pharmaceutical industry -- Licensing, certification and accreditation, Licenses -- Management, Avian influenza -- Drug therapy, Company marketing practices, Company business management, News, opinion and commentary, Tamiflu (Medication) -- Licensing, certification and accreditation, Tamiflu (Medication) -- Marketing
Abstract

As international pressure mounts, Roche Holding Ltd. is considering the licensing of its antiviral drug Tamiflu. The drug is considered the best treatment for avian flu.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results